TransMedics Group, Inc. โ NASDAQ:TMDX
Founder-led company
TransMedics Group stock price today
$122
+60.98
+99.93%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
TransMedics Group stock price monthly change
-57.09%
month
TransMedics Group stock price quarterly change
-57.09%
quarter
TransMedics Group stock price yearly change
-24.24%
year
TransMedics Group key metrics
Market Cap | 2.10B |
Enterprise value | N/A |
P/E | -57.55 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 22.56 |
Price/Book | 11.25 |
PEG ratio | -1.83 |
EPS | -0.32 |
Revenue | 296.91M |
EBITDA | 1.31M |
Income | -10.19M |
Revenue Q/Q | 133.07% |
Revenue Y/Y | 149.23% |
Profit margin | -38.77% |
Oper. margin | -33.64% |
Gross margin | 69.84% |
EBIT margin | -33.64% |
EBITDA margin | 0.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want toย keep trackย of and getย notified inย theย smart feed every time fresh news arrives.
Sign up for freeTransMedics Group stock price history
TransMedics Group stock forecast
TransMedics Group financial statements
| Jun 2023 | 52.46M | -1.00M | -1.91% |
|---|---|---|---|
| Sep 2023 | 66.43M | -25.42M | -38.27% |
| Dec 2023 | 81.17M | 4.03M | 4.97% |
| Mar 2024 | 96.85M | 12.19M | 12.59% |
| Dec 2023 | 81.17M | 4.03M | 4.97% |
|---|---|---|---|
| Mar 2024 | 96.85M | 12.19M | 12.59% |
| Oct 2025 | 133.73M | 8.49M | 6.35% |
| Dec 2025 | 139.50M | 9.18M | 6.59% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 690358000 | 545.14M | 78.97% |
|---|---|---|---|
| Sep 2023 | 689227000 | 562.76M | 81.65% |
| Dec 2023 | 706047000 | 568.84M | 80.57% |
| Mar 2024 | 723831000 | 564.36M | 77.97% |
| Jun 2023 | -5.80M | -1.38M | 394.01M |
|---|---|---|---|
| Sep 2023 | -6.86M | -149.82M | 1.52M |
| Dec 2023 | 8.30M | -41.81M | 924K |
| Mar 2024 | -3.43M | -44.17M | 3.18M |
TransMedics Group alternative data
Organ transplantation
| 21 May 2023 | 38 | 0 | 75 |
|---|---|---|---|
| 28 May 2023 | 11 | 0 | 76 |
| 4 Jun 2023 | 22 | 0 | 56 |
| 11 Jun 2023 | 11 | 0 | 66 |
| 18 Jun 2023 | 22 | 0 | 64 |
| 25 Jun 2023 | 29 | 0 | 64 |
| 2 Jul 2023 | 13 | 0 | 54 |
| 9 Jul 2023 | 27 | 0 | 66 |
| 16 Jul 2023 | 23 | 0 | 49 |
| 23 Jul 2023 | 22 | 0 | 44 |
| 30 Jul 2023 | 17 | 0 | 61 |
| 6 Aug 2023 | 19 | 0 | 76 |
| 13 Aug 2023 | 23 | 0 | 65 |
| 20 Aug 2023 | 25 | 0 | 42 |
| 27 Aug 2023 | 21 | 0 | 68 |
| 3 Sep 2023 | 16 | 0 | 54 |
| 10 Sep 2023 | 28 | 0 | 74 |
| 17 Sep 2023 | 26 | 0 | 48 |
| 24 Sep 2023 | 24 | 0 | 44 |
| 1 Oct 2023 | 23 | 0 | 64 |
Transmedics Group Inc
| 21 May 2023 | 22 |
|---|---|
| 28 May 2023 | 8 |
| 4 Jun 2023 | 20 |
| 11 Jun 2023 | 20 |
| 18 Jun 2023 | 0 |
| 25 Jun 2023 | 19 |
| 2 Jul 2023 | 22 |
| 9 Jul 2023 | 10 |
| 16 Jul 2023 | 20 |
| 23 Jul 2023 | 12 |
| 30 Jul 2023 | 0 |
| 6 Aug 2023 | 20 |
| 13 Aug 2023 | 7 |
| 20 Aug 2023 | 11 |
| 27 Aug 2023 | 0 |
| 3 Sep 2023 | 14 |
| 10 Sep 2023 | 0 |
| 17 Sep 2023 | 14 |
| 24 Sep 2023 | 13 |
| 1 Oct 2023 | 0 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Jan 2025 | 10 |
|---|---|
| Feb 2025 | 7 |
| Aug 2023 | 212 |
|---|---|
| Sep 2023 | 212 |
| Oct 2023 | 212 |
| Nov 2023 | 212 |
| Dec 2023 | 212 |
| Jan 2024 | 212 |
| Feb 2024 | 212 |
| Mar 2024 | 584 |
| Apr 2024 | 584 |
| May 2024 | 584 |
| Jun 2024 | 584 |
| Jul 2024 | 584 |
TransMedics Group other data
95.24%
+13.44%
of TMDX is owned by hedgeย funds
161
+32
26.65M
+3.78M
shares is hold by hedgeย funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 27330 |
| Feb 2024 | 0 | 26969 |
| Mar 2024 | 0 | 41700 |
| Apr 2024 | 0 | 60900 |
| May 2024 | 0 | 245888 |
| Jun 2024 | 0 | 703 |
| Aug 2024 | 0 | 96429 |
| Sep 2024 | 0 | 11585 |
| Oct 2024 | 0 | 11583 |
| Nov 2024 | 0 | 9291 |
| Dec 2024 | 0 | 1084 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KHAYAL TAMER I officer: Chief Co.. | Common Stock | 1,084 | $13.28 | $14,396 | ||
Sale | KHAYAL TAMER I officer: Chief Co.. | Common Stock | 1,084 | $86.4 | $93,658 | ||
Option | KHAYAL TAMER I officer: Chief Co.. | Stock Option (Right to Buy) | 1,084 | $13.28 | $14,396 | ||
Option | KHAYAL TAMER I officer: Chief Co.. | Common Stock | 1,458 | $38.46 | $56,075 | ||
Sale | KHAYAL TAMER I officer: Chief Co.. | Common Stock | 1,458 | $90.04 | $131,278 | ||
Option | KHAYAL TAMER I officer: Chief Co.. | Stock Option (Right to Buy) | 1,458 | $38.46 | $56,075 | ||
Option | BASILE EDWARD M director | Common Stock | 6,750 | $28.12 | $189,810 | ||
Sale | BASILE EDWARD M director | Common Stock | 5,296 | $83.35 | $441,422 | ||
Sale | BASILE EDWARD M director | Common Stock | 1,454 | $84.3 | $122,572 | ||
Option | BASILE EDWARD M director | Stock Option (Right to Buy) | 6,750 | $28.12 | $189,810 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
TransMedics: Q2 Analyst Estimates Will Fall Short
TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy
TransMedics: Extremely Undervalued And Extremely Innovative
TransMedics: Exceptional Q1 Undermines The Short Narrative
TransMedics: Get Some Exposure Despite Market Concerns
Stock Picks From Seeking Alpha's March 2025 New Analysts
Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market
Breaking Into Healthcare: Why TransMedics Is My Bold First Move
5 Cheap Growth Stocks For 2025
-
What's the price of TransMedics Group stock today?
One share of TransMedics Group stock can currently be purchased for approximately $122.
-
When is TransMedics Group's next earnings date?
Unfortunately, TransMedics Group's (TMDX) next earnings date is currently unknown.
-
Does TransMedics Group pay dividends?
No, TransMedics Group does not pay dividends.
-
How much money does TransMedics Group make?
TransMedics Group has a market capitalization of 2.10B and it's past yearsโ income statements indicate that its last revenue has increased compared to the previous period by 158.53% to 241.62M US dollars.
-
What is TransMedics Group's stock symbol?
TransMedics Group, Inc. is traded on the NASDAQ under the ticker symbol "TMDX".
-
What is TransMedics Group's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of TransMedics Group?
Shares of TransMedics Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TransMedics Group's key executives?
TransMedics Group's management team includes the following people:
- Dr. Waleed H. Hassanein Founder, MD, Chief Executive Officer, Pres & Director(age: 57, pay: $939,730)
- Dr. Tamer I. Khayal Chief Commercial Officer(age: 56, pay: $533,690)
- Mr. Stephen Gordon Chief Financial Officer. Treasurer & Sec.(age: 57, pay: $512,340)
-
Is TransMedics Group founder-led company?
Yes, TransMedics Group is a company led by its founder Dr. Waleed H. Hassanein.
-
How many employees does TransMedics Group have?
As Jul 2024, TransMedics Group employs 584 workers.
-
When TransMedics Group went public?
TransMedics Group, Inc. is publicly traded company for more then 6 years since IPO on 2 May 2019.
-
What is TransMedics Group's official website?
The official website for TransMedics Group is transmedics.com.
-
Where are TransMedics Group's headquarters?
TransMedics Group is headquartered at 200 Minuteman Road, Andover, MA.
-
How can i contact TransMedics Group?
TransMedics Group's mailing address is 200 Minuteman Road, Andover, MA and company can be reached via phone at 978 552 0900.
TransMedics Group company profile:
TransMedics Group, Inc.
transmedics.comExchange:
NASDAQ
Full time employees:
584
Industry:
Medical - Devices
Sector:
Healthcare
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
200 Minuteman Road
Andover, MA 01810
Andover, MA 01810
CIK: 0001756262
ISIN: US89377M1099
CUSIP: 89377M109
